## Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Hacisuleyman E, Hale C, Saito Y, et al. Vaccine breakthrough infections with SARS-CoV-2 variants. N Engl J Med. DOI: 10.1056/NEJMoa2105000

## Appendix

Figure S1: Standard curve for the chemically inactivated SARS-CoV-2

Table S1: Demographics on vaccinated and unvaccinated cohorts tested at the Rockefeller University between 1/21/2021 and 3/17/2021

Table S2: Multiplex primers for the SARS-CoV-2 RT-PCR assay

Table S3: Viral loads in Patient 1 and 2



Figure S1: Standard curve for the chemically inactivated SARS-CoV-2. Standard curve calculated using the chemically inactivated SARS-CoV-2 in DRUL buffer and extracted with SPRI magnetic beads. Patient 1's viral load at diagnosis corresponds to 134,000 and 255,000 copies per ml for N1 and N2, respectively. Patient 2's viral load at diagnosis corresponds to 400 and 450 copies per ml for N1 and N2, respectively.

Table S1: Demographics on vaccinated and unvaccinated cohorts tested at the Rockefeller University between 1/21/2021 and 3/17/2021. Vaccinated refers to participants who were at least 2 weeks beyond the second dose of either Pfizer/BioNTech or Moderna vaccines by 3/17/2021.

	Vaccinated Cohort (n=417)		Unvaccinated Cohort (n=149	
Gender				
Female	186	44.60%	698	46.81%
Male	226	54.20%	780	52.31%
Other	5	1.20%	13	0.87%
Average age (years)	47.2		34.9	
Ethnicity				
Not hispanic	324	77.70%	299	20.05%
Hispanic	65	15.59%	1063	71.29%
Not reported	28	6.71%	129	8.65%
Race				
White	253	60.67%	708	47.48%
Black	36	8.63%	153	10.26%
Asian	59	14.15%	332	22.27%
More than one	22	5.28%	88	5.90%
Unknown/unreported	45	10.79%	203	13.62%
Native American	2	0.48%	4	0.27%
Pacific Islander	0	0.00%	3	0.20%

Education					
College Grad	346	82.97%	1059	71.03%	
Some College	27	6.47%	131	8.79%	
High School Graduate	36	8.63%	149	9.99%	
Some High School	5	1.20%	27	1.81%	
Under 18 years old	0	0.00%	125	8.38%	
Unreported	3	0.72% 0		0.00%	
Health Care worker					
No	352	84.41%	1484	99.53%	
Yes	65	15.59%	7	0.47%	
First responder					
No	406	97.36%	1480	99.26%	
Yes	11	2.64%	11	0.74%	
Use public Transportation					
No	336	80.58%	1139	76.39%	
Yes	81	19.42%	352	23.61%	
Net PCR Test Results					
Positive	2	0.48%	32	2.15%	

Custom Primer / Probes	Manufacturer	Storage
SARS-CoV-2 forward primer for N1 target	LGC Biosearch	Room
(nCoV_NF1)	Technologies	temp
SARS-CoV-2 reverse primer for N1 target	LGC Biosearch	Room
(nCoV_NR1)	Technologies	temp
SARS-CoV-2 FAM probe for N1 target	LGC Biosearch	Room
(nCoV_NP1)	Technologies	temp
SARS-CoV-2 forward primer for N2 target	LGC Biosearch	Room
(nCoV_NF2)	Technologies	temp
SARS-CoV-2 reverse primer for N2 target	LGC Biosearch	Room
(nCoV_NR2)	Technologies	temp
SARS-CoV-2 Quasar 670 probe for N2 target	LGC Biosearch	Room
(nCoV_NP2)	Technologies	temp
	LGC Biosearch	Room
RNAse P forward primer (RP_F)	Technologies	temp
	LGC Biosearch	Room
RNAse P reverse primer (RP_R)	Technologies	temp
	LGC Biosearch	Room
RNAse P CAL Fluor Orange 560 probe (RP_P)	Technologies	temp

Table S2: Multiplex primers for the SARS-CoV-2 RT-PCR assay

Table S3: Viral loads in Patient 1 and 2

		Patient 1				Patient 2
Ct	Date:	3/10/2021	3/11/2021	3/12/2021	3/16/2021	3/18
N1		24.2	26.3	22.9	35.8	33.3
N2		23.5	25.9	22.4	35.9	33.1
RP		21.7	22.9	20.8	22.5	24.4